drugset / Trial / NCT04627246
Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
Phase Ib clinical trial using Autologous Dendritic Cell Vaccine Loaded with Personalized Peptides (PEP) in order to stimulate/induce both innate and adaptive immunity by activating T-cells and Natural Killer (NK) cells, combined with standard of care (SOC) adjuvant chemotherapy, followed by nivolumab, an antibody against Programmed Cell Death 1 (PD-1), to maintain and boost the vaccine's effect in patients with non-metastatic resectable pancreatic adenocarcinoma
Timeline
- Start
- 2020-09-11
- Primary completion
- 2028-09
- Completion
- 2028-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PEP-DC vaccine | Vaccine | — | Subcutaneous |
| Background | Capecitabine | Small molecule | — | Oral |
| Background | Gemcitabine | Small molecule | — | Intravenous |
| Background | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |